Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P05120

UPID:
PAI2_HUMAN

ALTERNATIVE NAMES:
Monocyte Arg-serpin; Placental plasminogen activator inhibitor; Serpin B2; Urokinase inhibitor

ALTERNATIVE UPACC:
P05120; Q96E96

BACKGROUND:
The protein Plasminogen activator inhibitor 2, with alternative names including Urokinase inhibitor and Serpin B2, inhibits the urokinase-type plasminogen activator. This inhibition is essential for controlling the breakdown of blood clots, distinguishing PAI-2 from other inhibitors like PAI-1, which is derived from endothelial cells.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Plasminogen activator inhibitor 2 offers a promising avenue for identifying novel therapeutic approaches. Given its significant role in modulating the fibrinolytic system, targeting PAI-2 could lead to breakthroughs in treating conditions associated with excessive clotting or bleeding.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.